The glycosphingolipid GD2 as an effective but enigmatic target of passive immunotherapy in children with aggressive neuroblastoma (HR-NBL)

U Rovigatti - Cancer Letters, 2021 - Elsevier
Neuroblastoma (NBL), the most frequent and lethal pediatric cancer of children in pre-school
age, is considered enigmatic in view of its extreme heterogeneity, from spontaneous …
被引用次数：4 相关文章

The Glycosphingolipid GD2 as an Effective but Enigmatic Target of Passive Immunotherapy in Children with Aggressive Neuroblastoma (HR-NBL)

U Rovigatti - INTERNATIONAL JOURNAL OF MOLECULAR …, 2020 - flore.unifi.it
Neuroblastoma (NBL), the most frequent and lethal pediatric cancer of children in pre-school
age, is still considered enigmatic. This is in view of its extreme heterogeneity, from …

The glycosphingolipid GD2 as an effective but enigmatic target of passive immunotherapy in children with aggressive neuroblastoma (HR-NBL).

U Rovigatti - Cancer Letters, 2020 - europepmc.org
Neuroblastoma (NBL), the most frequent and lethal pediatric cancer of children in pre-school
age, is considered enigmatic in view of its extreme heterogeneity, from spontaneous …

The glycosphingolipid GD2 as an effective but enigmatic target of passive immunotherapy in children with aggressive neuroblastoma (HR-NBL)

U Rovigatti - Cancer Letters, 2021 - Elsevier
Neuroblastoma (NBL), the most frequent and lethal pediatric cancer of children in pre-school
age, is considered enigmatic in view of its extreme heterogeneity, from spontaneous …

The glycosphingolipid GD2 as an effective but enigmatic target of passive immunotherapy in children with aggressive neuroblastoma (HR-NBL)

U Rovigatti - Cancer letters, 2021 - pubmed.ncbi.nlm.nih.gov
Neuroblastoma (NBL), the most frequent and lethal pediatric cancer of children in pre-school
age, is considered enigmatic in view of its extreme heterogeneity, from spontaneous …